What is Wiskott-Aldrich syndrome?
Wiskott-Aldrich syndrome (WAS) is a rare, inherited immunodeficiency disorder that primarily affects males and disrupts the immune system, blood clotting, and skin barrier function. The condition is caused by mutations in the WAS gene on the X chromosome, leading to defective white blood cell function and abnormally small platelets. WAS affects approximately 1-10 per million male births worldwide, making it one of the rarer primary immunodeficiencies. The syndrome was first described by pediatrician Robert Wiskott in 1937 and further characterized by immunologist Robert Aldrich in 1954.
Key statistics
| Prevalence | 1-10 per million male births |
| Age of onset | Birth to early infancy |
| Inheritance | X-linked recessive |
| Carrier frequency | Approximately 1 in 250,000 women |
Symptoms
Eczema, thrombocytopenia with small platelets, bleeding episodes, recurrent infections, autoimmune complications, increased cancer risk.
The classic triad of WAS symptoms typically appears in early infancy and includes severe eczema, bleeding problems due to low platelet counts, and recurrent infections. The eczema often begins within the first few months of life and can be particularly severe and difficult to treat, affecting the face, scalp, and flexural areas. Bleeding manifestations include easy bruising, nosebleeds, bloody diarrhea, and prolonged bleeding after circumcision or other procedures. The characteristic small platelet size (microthrombocytopenia) is a key diagnostic feature.
Recurrent infections are common and may include ear infections, pneumonia, sinusitis, and skin infections. These infections can be more severe and persistent than typical childhood illnesses. As children grow older, autoimmune complications may develop, including inflammatory bowel disease, arthritis, kidney disease, and blood vessel inflammation. There is also a significantly increased risk of developing cancers, particularly lymphomas and leukemias, which becomes more pronounced with age.
Causes and risk factors
Wiskott-Aldrich syndrome is caused by mutations in the WAS gene located on the X chromosome. This gene provides instructions for making the WAS protein (WASP), which is essential for normal function of blood cells, particularly immune cells and platelets. The protein helps regulate the cytoskeleton – the structural framework that gives cells their shape and enables movement.
Since WAS follows an X-linked recessive inheritance pattern, affected individuals are almost exclusively male. Males have only one X chromosome, so a single mutated copy of the gene causes the disorder. Females with one mutated copy are typically carriers and usually do not show symptoms, though some may experience mild bleeding tendencies or immune abnormalities. Each son born to a carrier mother has a 50% chance of having WAS, while each daughter has a 50% chance of being a carrier.
The primary risk factor is having a family history of the condition, though approximately one-third of cases result from new (de novo) mutations with no family history.
Prevention
As an inherited genetic condition, Wiskott-Aldrich syndrome cannot be prevented through lifestyle measures or environmental modifications. However, genetic counseling and testing play crucial roles in family planning decisions. Carrier testing can identify women who carry a mutated copy of the WAS gene, allowing for informed reproductive choices.
Prenatal diagnosis is available through amniocentesis or chorionic villus sampling for families with a known WAS mutation. Preimplantation genetic diagnosis (PGD) may be an option for some families using in vitro fertilization. These approaches allow families to make informed decisions about pregnancy management and prepare for specialized medical care if needed.
Complications
Without appropriate treatment, Wiskott-Aldrich syndrome can lead to life-threatening complications. Severe bleeding episodes may result from the low platelet count, potentially causing internal hemorrhage or excessive blood loss during injuries or procedures. Recurrent and severe infections can lead to sepsis, organ damage, or chronic complications such as bronchiectasis from repeated lung infections.
Autoimmune complications affect approximately 40-70% of patients and may include inflammatory bowel disease, autoimmune hemolytic anemia, kidney disease, and vasculitis. These autoimmune manifestations can be particularly challenging to manage and may significantly impact quality of life.
The risk of developing hematologic malignancies, particularly B-cell lymphomas, increases substantially with age, affecting up to 25% of patients. These cancers tend to be aggressive and may develop in unusual locations such as the brain or gastrointestinal tract.
Diagnosis
Diagnosis of Wiskott-Aldrich syndrome requires a combination of clinical features, laboratory findings, and genetic testing. The classical diagnostic triad includes thrombocytopenia with small platelets (mean platelet volume typically less than 7 femtoliters), eczema, and recurrent infections.
Laboratory tests reveal low platelet counts, characteristically small platelet size, and various immune system abnormalities including low or absent WAS protein expression in blood cells. Flow cytometry can measure WASP expression in lymphocytes, providing supportive evidence for the diagnosis.
Genetic testing through DNA sequencing of the WAS gene confirms the diagnosis and identifies the specific mutation. This information is crucial for family counseling and treatment planning. Additional immunological studies may include lymphocyte proliferation assays, immunoglobulin levels, and assessment of T-cell and B-cell function.
Scoring systems such as the WAS clinical score help classify disease severity based on platelet count, eczema severity, infections, autoimmunity, and malignancy presence.
Treatment
Treatment of Wiskott-Aldrich syndrome is multifaceted and requires coordination among multiple medical specialties. Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment and is recommended for patients with severe disease. Early transplantation, ideally before age 5 and before the development of significant autoimmune complications or malignancy, offers the best outcomes.
Supportive care includes platelet transfusions for severe bleeding episodes, though these should be used judiciously to avoid alloplatelet immunization. Prophylactic antibiotics may prevent serious bacterial infections, and immunoglobulin replacement therapy can help boost immune function.
Immunosuppressive medications such as rituximab, sirolimus, and corticosteroids may be used to manage autoimmune complications. Severe eczema often requires aggressive topical therapy with calcineurin inhibitors and careful skin care.
Gene therapy represents a promising emerging treatment option, with early clinical trials showing encouraging results. This approach involves introducing a functional copy of the WAS gene into the patient’s stem cells.
Splenectomy may be considered for severe thrombocytopenia in patients who are not candidates for transplantation, though this increases infection risk and requires lifelong antibiotic prophylaxis.
Prognosis
The prognosis for Wiskott-Aldrich syndrome varies significantly depending on disease severity and access to treatment. Without treatment, the condition is often fatal in childhood due to bleeding, infections, or malignancy. Historically, the average life expectancy was approximately 11 years.
With modern supportive care, many patients survive into adulthood, though they face ongoing risks of autoimmune complications and malignancy. Hematopoietic stem cell transplantation can be curative, with overall survival rates of 80-90% when performed with matched related donors in young patients. Success rates are somewhat lower with alternative donors or in older patients with existing complications.
Patients who receive successful transplants can expect normalization of platelet counts, resolution of bleeding problems, and improved immune function. However, some may continue to experience mild immune abnormalities or autoimmune complications. Quality of life is generally good following successful transplantation.
Quality of life
Living with Wiskott-Aldrich syndrome requires careful attention to infection prevention, bleeding precautions, and skin care. Families must balance protection from infections with allowing children to participate in normal activities. Good hygiene practices, avoiding crowds during illness outbreaks, and staying current with vaccinations (using inactivated vaccines only) are essential.
Contact sports and activities with high injury risk should be avoided due to bleeding tendencies. However, swimming, walking, and other low-impact activities are generally safe and beneficial. Skin care requires gentle, fragrance-free products and consistent moisturizing to manage eczema.
Educational support may be needed due to frequent medical appointments and hospitalizations. Many children with WAS have normal cognitive development and can participate fully in academic activities with appropriate accommodations.
Mental health support is important for both patients and families, as living with a chronic, life-threatening condition can cause anxiety and stress. Connecting with other families through patient organizations provides valuable emotional support and practical advice.
Pregnancy and fertility
Males with Wiskott-Aldrich syndrome can father children, though the bleeding risks and potential need for medical procedures require careful management. Fertility is generally not directly affected by the condition itself.
For carrier females, pregnancy is typically uncomplicated, though some may experience mild bleeding tendencies that require monitoring during delivery. Prenatal diagnosis and genetic counseling are strongly recommended for all at-risk pregnancies.
Treatment medications may affect pregnancy planning, and women of childbearing age should discuss contraception and family planning with their healthcare team well in advance of any planned pregnancy.
Children
Wiskott-Aldrich syndrome presents unique challenges in pediatric care, as symptoms typically appear in infancy. Early recognition and prompt treatment are crucial for optimal outcomes. Children require close monitoring by pediatric immunologists and hematologists.
School accommodations may include provisions for frequent absences, modified physical education activities, and infection control measures. Teachers and school nurses should be educated about the condition and emergency procedures for bleeding episodes.
Growth and development are usually normal with appropriate medical management, though chronic illness may occasionally affect growth velocity. Regular developmental assessments ensure any delays are identified and addressed promptly.
When to see a doctor
Immediate medical attention is required for signs of serious bleeding, including persistent nosebleeds, blood in vomit or stool, severe headaches, or any significant trauma. High fever, difficulty breathing, or signs of severe infection also warrant emergency care.
Routine medical care should include regular monitoring of blood counts, immune function, and screening for complications. Any new or worsening symptoms, including changes in bleeding patterns, new skin lesions, persistent fatigue, or unexplained weight loss, should be evaluated promptly.
Families should maintain close communication with their medical team and have clear action plans for common complications such as bleeding episodes or infections.
Regional context
Specific prevalence data for Wiskott-Aldrich syndrome in the Caucasus region (Georgia, Armenia, Azerbaijan) is limited due to the rarity of the condition and potential underdiagnosis in some areas. However, the global prevalence of 1-10 per million male births likely applies to this region as well.
Access to specialized immunology care and stem cell transplantation may vary across the region, potentially affecting outcomes for affected individuals. We invite healthcare professionals and researchers from Georgia, Armenia, and Azerbaijan to contribute regional data and insights about WAS diagnosis and management to the Global Medical Journal.
Research and clinical trials
Current research focuses on improving gene therapy approaches, developing new conditioning regimens for stem cell transplantation, and better understanding the molecular mechanisms underlying WAS pathogenesis. Gene therapy trials using lentiviral vectors have shown promising results, with some patients achieving stable engraftment and clinical improvement.
Researchers are also investigating novel treatment approaches, including gene editing techniques and small molecule therapies that might bypass the need for stem cell transplantation. Studies examining optimal timing and conditioning protocols for transplantation continue to refine treatment approaches.
Information about current clinical trials can be found at ClinicalTrials.gov, where patients and families can search for relevant studies. Participation in research studies may provide access to experimental treatments while contributing to improved understanding of the condition.
Frequently asked questions
Is Wiskott-Aldrich syndrome contagious?
No, Wiskott-Aldrich syndrome is a genetic condition present from birth and cannot be transmitted to others through contact, sharing food, or any other means.
Can females have Wiskott-Aldrich syndrome?
While extremely rare, females can be affected if they inherit two mutated copies of the WAS gene or have certain chromosomal abnormalities. Most females with one mutated copy are healthy carriers.
What is the difference between WAS and X-linked thrombocytopenia?
X-linked thrombocytopenia (XLT) is a milder form of the same genetic condition, typically involving only bleeding problems without the severe infections, eczema, or autoimmune complications seen in classic WAS.
Can stem cell transplantation cure Wiskott-Aldrich syndrome?
Yes, successful stem cell transplantation can cure WAS by replacing the defective immune and blood cell systems with healthy donor cells. However, the procedure carries risks and requires careful evaluation of timing and donor selection.
Are there any dietary restrictions for people with WAS?
While there are no specific dietary restrictions, maintaining good nutrition is important for immune function. Some patients may need to avoid raw or undercooked foods to reduce infection risk, and those on certain medications may have additional dietary considerations.
Support and resources
– Immune Deficiency Foundation: https://primaryimmune.org
– International Patient Organisation for Primary Immunodeficiencies (IPOPI): https://ipopi.org
– European Society for Primary Immunodeficiencies (ESID): https://esid.org
– National Organization for Rare Disorders (NORD): https://rarediseases.org
– Orphanet: https://orpha.net
– EURORDIS (European Organisation for Rare Diseases): https://eurordis.org
– Jeffrey Modell Foundation: https://info4pi.org
Related conditions
– Severe combined immunodeficiency (SCID)
– Chronic granulomatous disease
– X-linked agammaglobulinemia
– Immune thrombocytopenic purpura
– Ataxia-telangiectasia
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Wiskott-Aldrich syndrome.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/wiskott-aldrich-syndrome/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?